STOCK TITAN

Amicus Therapeutics, Inc - FOLD STOCK NEWS

Welcome to our dedicated news page for Amicus Therapeutics (Ticker: FOLD), a resource for investors and traders seeking the latest updates and insights on Amicus Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Amicus Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Amicus Therapeutics's position in the market.

Rhea-AI Summary
FOLD: Amicus Therapeutics Announces 27% Increase in Total Revenue to $103.5M in 3Q 2023, Galafold® Quarterly Revenue Surpasses $100M for the First Time, Pombiliti™ + Opfolda™ Approved and Launched in the U.S., EU, and U.K., Non-GAAP Profitability Projected in Q4 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.99%
Tags
-
Rhea-AI Summary
Amicus Therapeutics (Nasdaq: FOLD) will participate in investor conferences in November. The UBS Biopharma Conference will be held on November 9th at 1:00 p.m. E.T. in Miami, FL. The Stifel 2023 Healthcare Conference will be held on November 15th at 8:00 a.m. E.T. in New York, NY. The presentations can be accessed via the Amicus Therapeutics corporate website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.09%
Tags
conferences
-
Rhea-AI Summary
Amicus Therapeutics to host conference call and webcast to discuss Q3 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
Rhea-AI Summary
Amicus Therapeutics announces presentation at World Muscle Society Congress on development program for Pompe disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Amicus Therapeutics announces a $430 million financing collaboration with Blackstone, including a $400 million senior secured term loan and a $30 million strategic investment in Amicus's common stock. The refinancing of existing debt will reduce the interest rate, extend the amortization period, and push out the amortization schedule. The loan facility requires interest-only payments until late 2026 and matures in October 2029. The proceeds will be used to refinance Amicus's existing debt and fund ongoing operations. The collaboration demonstrates Blackstone's commitment to Amicus's future and belief in the strong growth potential of their medicines for rare diseases. The loan is expected to be funded and the equity investment is expected to close on October 5, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.29%
Tags
none
-
Rhea-AI Summary
WuXi Biologics congratulates Amicus Therapeutics on FDA approval for Pombiliti™ and Opfolda™ for late-onset Pompe disease. WuXi Biologics is the exclusive manufacturing partner for the therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.29%
Tags
Rhea-AI Summary
Amicus Therapeutics receives FDA approval for Pombiliti™ and Opfolda™ two-component therapy for late-onset Pompe disease, leading to positive impact on stock price.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.92%
Tags
-
Rhea-AI Summary
Amicus Therapeutics to participate in investor conferences in September
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
conferences
-
Rhea-AI Summary
Amicus Therapeutics (Nasdaq: FOLD) to present at SSIEM Annual Symposium 2023 in Jerusalem, Israel.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
none
Rhea-AI Summary
WuXi Biologics reports solid business performance with sustained growth momentum and strong backlog
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
none
Amicus Therapeutics, Inc

Nasdaq:FOLD

FOLD Rankings

FOLD Stock Data

3.09B
222.12M
0.75%
109.94%
11%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
PHILADELPHIA

About FOLD

amicus therapeutics is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. we have a unique set of platform technologies and medicines in development for patients living with the lysosomal storage disorders fabry disease and pompe disease and we are committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for these and other rare diseases. the needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers. several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. our amicus footprint spans 27 countries including our g